Marketing authorisation recommended to be withdrawn for preterm birth drug
A vote by an FDA committee has resulted in the suggestion that marketing authorisation is revoked for preterm birth treatment Makena.
List view / Grid view
A vote by an FDA committee has resulted in the suggestion that marketing authorisation is revoked for preterm birth treatment Makena.
The FDA has announced its approval of a therapy for hypoactive sexual desire disorder in premenopausal women.